Clinical Trials Galore!
The MajesTEC trials are being reported quite a bit it seems. These are studies with Tecvayli, or teclistamab (that’s the TEC). I watched/listened to about MajesTEC 5, 4, and 2. Each looked at different dosing and combos, and each study showed that teclistamab comes with neutropenia, so most all needed IVIG during their treatment.
A new drug, ABBV-383 (now named Etentamig) is being tested in relapsed or refractory (R/R) patients who have had more than three lines of therapy. They’re testing it with either Pomalyst (pomalidomide), Revlimid (lenalidomide), or Darzalex (daratumumab)—(all with dex, sorry). The Eten/dara/dex arm showed an overall response rate (ORR) of 83%.
Blenrep (belantamab mafodotin) is back in trial after being approved and then promptly recalled by the FDA. Dr. Saad Usmani reported on the DreaMM-9 trial with bela plus Velcade (bortezomib), Revlimid (lenalidomide),and dex, or VRd. The ocular concerns are part of the issues for patients who must see an ophthalmologist before each infusion.
A novel BCMAxCD3 bispecific antibody is in phase 1 trials for R/R multiple myeloma patients. I’m really not qualified to comment on this—all I could see was that 40 patients were enrolled and 35 discontinued. That seems like a pretty high attrition rate! But time will tell if there is a population who needs this. He said the five remaining on the trial are doing well on a compassionate need basis. So, they may not have any options.
There were more studies with teclistamab, including a retrospective study of real-world data comparing fit versus frail older people. Interesting that TEC showed similar outcomes.